The Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer's disease — despite an FDA advisory committee concluding last year that there is not enough evidence to support the effectiveness of the treatment. The drug was developed for patients with mild cognitive impairment, not severe dementia, and intended to slow progression of Alzheimer's disease — not just ease symptoms.
The FDA has not approved a new Alzheimer's drug in nearly 20 years.
Read More:
